Entero Therapeutics Appoints Richard Paolone as CEO
Entero Therapeutics (Nasdaq: ENTO) has announced the appointment of Richard Paolone as interim CEO. Paolone, a Toronto-based securities lawyer, brings extensive experience in corporate finance, securities law, and mergers and acquisitions to the clinical-stage biopharmaceutical company.
Paolone's background includes advising on strategic business initiatives, representing companies in debt and equity securities offerings, and demonstrating comprehensive knowledge of capital markets and regulatory environments. He has been instrumental in numerous M&A and go-public transactions, and has served as a director or officer for multiple private and publicly traded companies.
Entero Therapeutics (Nasdaq: ENTO) ha annunciato la nomina di Richard Paolone come CEO ad interim. Paolone, un avvocato specializzato in titoli con sede a Toronto, porta con sé una vasta esperienza in finanza aziendale, diritto dei titoli e fusioni e acquisizioni per la società biofarmaceutica in fase clinica.
Il background di Paolone include la consulenza su iniziative aziendali strategiche, la rappresentanza di aziende in offerte di titoli di debito e capitale, e una conoscenza approfondita dei mercati dei capitali e degli ambienti normativi. È stato fondamentale in numerose operazioni di M&A e di quotazione, e ha ricoperto ruoli di direttore o funzionario in diverse aziende private e quotate in borsa.
Entero Therapeutics (Nasdaq: ENTO) ha anunciado el nombramiento de Richard Paolone como CEO interino. Paolone, un abogado de valores con sede en Toronto, aporta una amplia experiencia en finanzas corporativas, legislación de valores y fusiones y adquisiciones a la compañía biofarmacéutica en etapa clínica.
El historial de Paolone incluye asesorar en iniciativas empresariales estratégicas, representar a empresas en ofertas de valores de deuda y capital, y demostrar un conocimiento integral de los mercados de capitales y los entornos regulatorios. Ha sido fundamental en numerosas transacciones de M&A y de salida a bolsa, y ha ocupado cargos de director u oficial en múltiples empresas privadas y cotizadas.
Entero Therapeutics (Nasdaq: ENTO)는 Richard Paolone를 임시 CEO로 임명했다고 발표했습니다. 토론토에 본사를 둔 증권 변호사인 Paolone은 임상 단계의 생명공학 회사에 대한 기업 금융, 증권법, 인수합병에 대한 광범위한 경험을 제공합니다.
Paolone의 배경은 전략적 비즈니스 이니셔티브에 대한 자문, 부채 및 자본 증권 제공에서 기업을 대리하는 것, 자본 시장 및 규제 환경에 대한 포괄적인 지식을 보여주는 것을 포함합니다. 그는 수많은 인수합병 및 상장 거래에서 중요한 역할을 했으며, 여러 개의 비상장 및 상장 회사에서 이사 또는 임원으로 활동했습니다.
Entero Therapeutics (Nasdaq: ENTO) a annoncé la nomination de Richard Paolone en tant que PDG par intérim. Paolone, un avocat spécialisé en valeurs mobilières basé à Toronto, apporte une vaste expérience en finance d'entreprise, droit des valeurs mobilières et fusions-acquisitions à cette société bio-pharmaceutique en phase clinique.
Le parcours de Paolone comprend des conseils sur des initiatives commerciales stratégiques, la représentation d'entreprises dans des offres de titres de créance et de capital, et une connaissance approfondie des marchés de capitaux et des environnements réglementaires. Il a joué un rôle essentiel dans de nombreuses transactions de fusions et acquisitions ainsi que des introductions en bourse, et a occupé des postes de directeur ou d'officier dans plusieurs entreprises privées et cotées en bourse.
Entero Therapeutics (Nasdaq: ENTO) hat die Ernennung von Richard Paolone zum interimistischen CEO bekannt gegeben. Paolone, ein in Toronto ansässiger Wertpapieranwalt, bringt umfassende Erfahrungen in den Bereichen Unternehmensfinanzierung, Wertpapierrecht sowie Fusionen und Übernahmen in das biopharmazeutische Unternehmen in der klinischen Phase ein.
Paolones Hintergrund umfasst die Beratung zu strategischen Geschäftsinitiativen, die Vertretung von Unternehmen bei der Emission von Schuldtiteln und Eigenkapital sowie umfassendes Wissen über die Kapitalmärkte und regulatorische Rahmenbedingungen. Er war maßgeblich an zahlreichen M&A-Transaktionen und Börsengängen beteiligt und hat in mehreren privaten und börsennotierten Unternehmen als Direktor oder leitender Angestellter gedient.
- Appointment of an experienced corporate finance and M&A professional as interim CEO
- New CEO brings extensive experience in capital markets and regulatory compliance
- Strong background in both private and public offerings of securities
- Interim nature of the CEO appointment indicates potential temporary leadership
- New CEO's background is primarily in legal and financial sectors rather than biotechnology or pharmaceuticals
BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company.
Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt and equity securities, comprehensive understanding of capital markets and regulatory environments. His advisory work has been pivotal to several successful M&A and go-public transactions.
In addition to his transactional work, Mr. Paolone has built a reputation as a trusted advisor to management teams and boards, ensuring legal and regulatory compliance in Canada while facilitating business growth. His broad experience also includes serving as a director or officer for several private and publicly traded companies, where he continues to provide strategic insights and governance expertise to help guide their success in competitive markets.
For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn.
About Entero Therapeutics
Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com.
For more information:
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@enterothera.com
Investor contact information:
Entero Investor Relations
investors@enterothera.com
FAQ
Who is the new interim CEO of Entero Therapeutics (ENTO)?
What is Richard Paolone's background before joining ENTO as interim CEO?
What are Richard Paolone's key areas of expertise as ENTO's new interim CEO?
When did Entero Therapeutics (ENTO) announce its new interim CEO appointment?
